Congenital adrenal hyperplasia stands at a critical juncture where cutting-edge medical research intersects with the harsh realities of clinical practice. The year 2024 has proven pivotal for CAH therapeutics, delivering both groundbreaking regulatory approvals and sobering developmental failures that collectively reshape our understanding of what’s possible in treating this complex endocrine disorder. When Promise Meets… Read.